Successful meetings held at the Taiwan Society for Plastic Surgery
We are happy to report an eventful exhibition over the weekend at the Taiwan Society for Plastic Surgery led by our distributor in Taiwan. This is the first time the Adtec SteriPlas has set foot in Taiwan so naturally there was a lot of interest in our medical device. We look forward supporting our distributor for the exciting year ahead.
For more information about our medical device, contact us at info@adtecplasma.com
The first cold plasma medical device to treat Scleroderma
We congratulate Dr Stephanie Ardnt and Prof. Sigrid Karrer from the University Hospital Regensburg for their recent publication, “The Anti-Fibrotic Effect of Cold Atmospheric Plasma on Localized Scleroderma In Vitro and In Vivo”.
This publication features the use of our Adtec SteriPlas and shows strong efficacy for the treatment of Scleroderma, which up to now has not yet been evaluated by CAP. The extensive study documents significantly reduced dermal thickness and collagen deposition as well as a decrease in both alpha smooth muscle actin-positive myofibroblasts and CD68-positive macrophages in the affected skin in comparison to untreated fibrotic tissue. This study provides the first evidence for the successful use of CAP for treating LS and may be the basis for clinical trials including patients with LS.
https://doi.org/10.3390/biomedicines9111545
Deep Sternal Wound Infections (DWSI) and the Adtec SteriPlas
Unlike other cold plasma medical devices currently present on the market, the Adtec SteriPlas is not limited to the treatment of superficial wounds only.
For example, deep sternal wound infections (DSWIs) are a potentially devastating complication of median sternotomy performed in cardiac surgery. These large wound cavities are prone to infections and there is a concerningly high morbidity and mortality rate associated to these patients. The use of conventional therapies alone has shown to not always be successful and expensive muscle flap surgery is usually required.
The large 12cm2 treatment area of the Adtec SteriPlas covers a greater surface area of the wound compared to its competitors. This allows the benefit of a quick 2 minute treatment time for every 12cm2 covered. Because of its propulsion towards the treatment site, the cold plasma components work quickly to defeat bacteria and allow the management of the infection. The use of the Adtec SteriPlas has shown to accelerate healing rates and prevent the need for expensive surgery options that would otherwise have been needed.
It has been praised as a lifesaving medical device and is now widely used across multiple hospitals for the management of DWSIs.
Quick results achieved with the Adtec SteriPlas
How often do LVAD patients with infection need treatment with the Adtec SteriPlas?
We recommend a minimum treatment of twice per week. This applies to both outpatients in day clinics and inpatients who have been admitted into the wards.
The treatment time itself is as quick as 3 minutes. During these short minutes, the components of cold plasma quickly bombard the cellular structure of bacteria to create micropores which allows access to the microbial DNA for total destruction. This applies to all forms of bacteria regardless of their resistance profile or if they are protected within biofilm.
How quick have patients with LVAD infections healed?
Our clinical evidence has shown patients have healed in as quick of two weeks of treatment. These are patients who have failed previous therapeutic attempts with conventional treatment methods.
Promising, consistent and reliable results achieved with the Adtec SteriPlas
Whilst Left ventricular assist devices (LVADs) have become essential mechanical pumps for patients who have had end stage heart failures, they are also prone to infections especially with the presence of biofilm that complicates treatment options. Cardiologists often rely on conventional antibiotic therapy but with rising antimicrobial resistance rates, they sometimes offer little to no help in achieving stabilisation.
The strong properties of the Adtec SteriPlas cold plasma has been proven to offer complete stabilisation of the LVAD system by destroying all forms of multi-resistant bacteria present, even if they are protected within biofilm. This is due to the unique cold plasma properties that can travel through the gaps around and down the driveline to reach the site of biofilm. This area would normally have been difficult to treat with conventional therapies such as antimicrobial dressings as they are hard to reach, but the Adtec SteriPlas has shown to travel to these sites with ease due to its remarkable antibacterial gaseous properties.
To learn more about our strong collection of clinical evidence, please contact us at info@adtecplasma.com to learn more
We welcome you to our new office
We are excited to introduce you to our new office layout. The renovation works have finally been completed at our new location and all of our staff are now back onsite to continue business as normal. We look forward to welcoming our customers and partners to our new office, as well as to meet you all soon at the upcoming exhibitions and customer meetings we have planned.
Adtec Healthcare has moved to Twickenham
It is official, we have moved!
We are proud to announce that due to our remarkable growth over the years and to serve you better with even more space, we have decided to expand our company and move location to a bigger office. Adtec Europe Ltd and Adtec Healthcare will now be based at the beautiful and leafy area of Twickenham.
Whilst the new office location is under renovation, the majority of our team will again be working from home, but customer visits and meetings will still take place as usual. We look forward to moving into our new office around mid-August once the renovations are completed.
Loyalty from customers like you has fueled our continued growth. Thank you for your ongoing support.
Safe UV and Reactive Species levels only with the Adtec SteriPlas
As a leading medical device company, the crucial balance of safety and clinical efficacy are a top priority. We are always conducting tests to demonstrate the approved safety and reliability of the Adtec SteriPlas but to also learn new ways to improve the use of cold plasma in medicine.
Our clinical studies already validate the safety of the Adtec SteriPlas, including its low-level UV and reactive species produced from the cold plasma. These two components are imperative for the physical destruction of bacteria, however, too much of a good thing can also be relatively damaging like that observed with cold plasma jet/pens and battery powered cold plasma devices.
Measured across multiple distances, the UV light produced is well below the ICNIRP limit of 30 J/m2 and the reactive species produced are well below the occupational limits set by NIOSH and UK HSE. The Adtec SteriPlas continues to be one of the only cold plasma medical devices that puts patient and user safety first with no reported side effects and promising clinical efficacy from every treatment conducted.
For more information about the Adtec SteriPlas, send us an email at info@adtecplasma.com
Adtec Healthcare prepares for exhibition in July
We are very excited to be exhibiting at the Malvern Diabetic Foot Conference between 7-9th July. This will be our first physical exhibition participation in over a year! Be sure to visit us and see our cold plasma medical device live in action, perfect for the treatment of chronic DFUs infected with biofilm.
E-poster at the EADV 2021 Conference
We look forward to supporting Fiona Koch’s e-poster that will be live during the EADV 2021 Spring Symposium tomorrow. Tune in to their website to get full access to her poster, “Efficacy of cold atmospheric plasma versus diclophenac 3% gel in patients with actinic keratoses: a prospective, randomized and rater-blinded study (ACTICAP)”.
To learn more about the Adtec SteriPlas’ strong clinical efficacy for the treatment of actinic keratoses, contact us at info@adtecplasma.com